CCM
ALXN

Catapult Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Catapult Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-20,000
Closed -$1.84M – 316
2013
Q2 		$1.84M Buy
+20,000
New +$1.93M 0.77% 37

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Catapult Capital Management's ALXN Position: Q3 2015 in Review

Catapult Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2015, closing a stake of 15,000 shares — an estimated $2.71M sold.

Catapult Capital Management first reported a position in ALXN in Q3 2013 and held it in 3 quarters. The position peaked at $3.9M in Q1 2015. 514 funds tracked by Wall St. Rank hold ALXN as of Q3 2015.

  • Catapult Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Catapult Capital Management sold 15,000 Alexion Pharmaceuticals shares in Q3 2015, an estimated $2.71M.
  • Catapult Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 3 quarters.
  • Catapult Capital Management's Alexion Pharmaceuticals position peaked at $3.9M in Q1 2015.
  • 514 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.